Promise Bio News
2 articles
growth-positive
The Israeli startup's computational platform uses epiproteomics and AI to predict patient treatment responses and support drug research and development.
Promise Bio, a startup focused on treating immune-mediated diseases with precision medicine, has emerged from stealth with an $8.3 million Seed investment. The funding round was led by Awz Ventures and included contributions from AstraZeneca, Pfizer, and the Israel Innovation Authority. This investment will accelerate the development of Promise Bios computational platform, which leverages epiproteomics and AI to predict patient treatment responses and support drug research. The platform, based on research by Dr. Assaf Kacen at the Weizmann Institute of Science, aims to improve the effectiveness of autoimmune disease treatments by focusing on protein modifications. The company seeks to eliminate the trial-and-error approach in current treatments, which only achieve significant remission in 30-40% of patients.
Investment
growth-positive
/PRNewswire/ -- Promise Bio, a startup transforming immune-mediated disease treatment with advanced precision medicine solutions, today announced its emergence...
Promise Bio, a startup focused on precision medicine for immune-mediated diseases, has emerged from stealth with an $8.3 million seed investment. The funding, led by Awz Ventures and supported by AION Labs, AstraZeneca, and Pfizer, will accelerate the development of Promise Bios platform that integrates epiproteomics and AI to predict patient treatment responses. The company aims to transform treatment approaches by focusing on protein modifications and leveraging machine learning. Strategic partnerships with leading biopharmaceutical companies provide financial backing and industry expertise, positioning Promise Bio to advance precision medicine solutions and build the worlds largest PTM database.
InvestmentPartners
